NASDAQ
5.07USD
+0.02 (+0.40%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
135.4M
P/E
—
EPS
—
Beta
1.79
52W range
3.71-8.74
Day range
5.04–5.21
Open
5.14
Prev close
5.05
Volume
489.8K
Avg volume
1.4M
Dividend
0.00
IPO
2021-07-12
https://www.globenewswire.com/news-release/2026/07/15/3327851/23044/en/SHAREHOLDER-ALERT-GPGI-Inc-Sued-for-Securities-Law-Violations-Investors-Should-Contact-Block-Leviton-To-Learn-How-They-Might-Recover-Their-Losses.html · 7/15/2026-1.00
https://www.globenewswire.com/news-release/2026/07/14/3327313/23044/en/PLNT-LAWSUIT-Planet-Fitness-Inc-Sued-for-Securities-Law-Violations-Investors-Should-Contact-Block-Leviton-To-Learn-How-They-Might-Recover-Their-Losses.html · 7/14/2026-0.50
https://www.globenewswire.com/news-release/2026/07/11/3325784/937/en/UNCY-INVESTOR-ALERT-Kirby-McInerney-LLP-Investigates-Potential-Claims-Involving-Unicycive-Therapeutics-Inc.html · 7/11/2026-1.00
https://www.newsfilecorp.com/release/304039/Unicycive-Therapeutics-ALERT-Securities-Fraud-Investigation-by-Block-Leviton-Could-Allow-Investors-to-Recover-Losses · 7/6/2026
https://www.globenewswire.com/news-release/2026/07/02/3321526/0/en/Johnson-Fistel-Investigates-the-Grindr-Board-for-Potential-Breaches-of-Fiduciary-Duties-Relating-to-the-Grindr-Buyout-Termination.html · 7/2/2026-0.60
https://www.globenewswire.com/news-release/2026/06/30/3320031/0/en/Johnson-Fistel-Investigates-Unicycive-Therapeutics-Inc-NASDAQ-UNCY-on-Behalf-of-Investors.html · 6/30/2026-1.00
https://seekingalpha.com/article/4907351-unicycive-therapeutics-uncy-stock-catalyst-play-with-real-fundamental-upside · 5/21/2026+0.00
https://seekingalpha.com/article/4891399-unicycive-therapeutics-inc-uncy-presents-at-25th-annual-needham-virtual-healthcare-conference · 4/16/2026+0.10
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-unicycive-therapeutics-inc-to-contact-law-firm-302738364.html · 4/9/2026-1.00
https://www.globenewswire.com/news-release/2025/11/03/3179112/0/en/Unicycive-Therapeutics-to-Participate-in-a-Fireside-Chat-at-the-Guggenheim-2nd-Annual-Healthcare-Innovation-Conference.html · 11/3/2025+0.10
https://www.globenewswire.com/news-release/2025/10/13/3165755/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Unicycive-Therapeutics-Inc-Investors.html · 10/13/2025-1.00
https://www.prnewswire.com/news-releases/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-unicycive-therapeutics-inc-and-certain-officers--uncy-302582099.html · 10/13/2025-1.00
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
